Pfizer: From Zero to Hero (Maybe)

by

Family looking at data

Folks, let’s talk about Pfizer. Yes, that Pfizer. The one that, for the last five years, has been performing about as well as a mime at a rock concert. Down 25%, while the S&P 500 was doing the cha-cha at 68%? Oy vey. Investors were starting to think the company’s future involved more questions than a philosophy exam. It was a sad, sad spectacle. Frankly, I’ve seen better returns from a penny stock based on a hamster’s racing performance.

But hold on to your hats, because something…unusual…is happening. Besides the dividend – which, let’s be honest, was the only reason anyone was still holding onto this stock – Pfizer is suddenly…outperforming the S&P 500. Yes, you heard that right. It’s like the ugly duckling suddenly discovered it was secretly a swan…or at least a slightly less unattractive duck. The market, it seems, is starting to panic, and when the market panics, it buys dividend stocks. It’s a simple equation, really. Fear plus dividends equals…well, a temporary reprieve from financial ruin.

Couple talking to advisor

The Last Time Pfizer Beat the Street (2022…A Distant Memory)

For the last couple of years, everyone was chasing growth stocks like they were free bagels. Pfizer? Forgotten. Left in the dust. Considered about as exciting as watching paint dry. In 2025, down 6%. 2024? Down 8%. And 2023? Don’t even ask. Down 44%! It was a bloodbath! Even in 2022, it dipped 13%, but hey, the S&P 500 was getting pummeled too, down 19%. Inflation was running wild, and everything was going to pot. That was the last time Pfizer managed to beat the market. A truly glorious moment…for Pfizer, anyway.

This year’s playing out the same way, for similar reasons. Worried about the economy? Check. Commodity prices going up? Double check. Multiple wars happening simultaneously? Triple check! It’s a recipe for disaster, folks! So, naturally, everyone’s rushing to buy stocks that pay dividends. It’s like we’ve learned nothing from history! Pfizer, with its 6.4% dividend yield, is looking awfully attractive right now. It’s the financial equivalent of a warm blanket on a cold day. A slightly tattered, slightly moth-eaten blanket, but a blanket nonetheless.

Loading widget...

Is Pfizer a Good Buy? (Don’t Ask Me, I’m Just a Storyteller)

Now, let’s not get carried away. Pfizer’s gains are still modest. Up 8% this year? That’s better than the S&P 500’s decline of 4%, but it’s hardly a reason to throw a parade. It’s like winning a raffle for a slightly used toaster. Still, it’s incredibly cheap, with a forward price-to-earnings multiple of just over nine. That’s practically giving it away!

This is a severely discounted stock, folks. And while there are still question marks about Pfizer’s future growth – will they ever recover from the patent cliffs? Will their acquisitions pay off? – the business is, at the very least, stable. Last year, revenue came in at $62.6 billion, a 2% operational decline. Not great, but not terrible either. It’s like a boxer who’s taken a few punches but is still standing. For a heavily discounted stock, that’s what you’d expect. And in the long run, it may have room to grow from all the acquisitions it has made in recent years. They’ve been buying up companies like they’re collecting stamps!

Pfizer faces some uncertainty, yes. But with such a low valuation, it offers investors a margin of safety that’s hard to find these days. Plus, it pays a high dividend. Overall, this may be one of the better stocks to buy right now, as Pfizer may be due for a prolonged rally this year. But remember, I’m just a storyteller, folks. Don’t blame me if your portfolio ends up looking like a shipwreck.

Read More

2026-03-23 23:03